Core Insights - BeOne Medicines Ltd. (NASDAQ:ONC) is recognized as one of the top high-growth European stocks to invest in, with a Market Outperform rating and a price target of $396 set by Citizens due to strong Phase 3 trial results in gastric cancer patients [1] - The HERIZON-GEA-01 trial demonstrated high efficacy in patients with advanced gastric or gastroesophageal adenocarcinoma (GEA), further supporting the company's growth potential [1] - BeOne's Brukinsa is projected to generate approximately $3.8 billion in revenue by 2025, bolstered by a robust development pipeline across various indications [2] - The company has achieved its first clearance for sonrotoclax, a next-generation BCL2 inhibitor, which is expected to lead to further approvals globally [2] - BeOne maintains a strong cash position of $4.1 billion, and the recent decline in share price is viewed as a "unique buying opportunity" in the hematology/oncology sector [3] - BeOne Medicines Ltd. specializes in oncology medicines, focusing on treatments for blood cancers and solid tumors [3]
Citizens Highlights BeOne Medicines’ (ONC) $3.8B Revenue Potential for 2025